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Abstract: Porcine reproductive and respiratory syndrome virus (PRRSV) causes severe respiratory
distress and reproductive failure in swine. Modified live virus (MLV) vaccines provide the highest
degree of protection and are most often the preferred choice. While somewhat protective, the use of
MLVs is accompanied by multiple safety issues, why safer alternatives are urgently needed. Here,
we describe the generation of virus replicon particles (VRPs) based on a classical swine fever virus
genome incapable of producing infectious progeny and designed to express conserved PRRSV-2
cytotoxic T-cell epitopes. Eighteen pigs matched with the epitopes by their swine leucocyte antigen-
profiles were vaccinated (N = 11, test group) or sham-vaccinated (N = 7, control group) with the
VRPs and subsequently challenged with PRRSV-2. The responses to vaccination and challenge
were monitored using serological, immunological, and virological analyses. Challenge virus load
in serum did not differ significantly between the groups, whereas the virus load in the caudal part
of the lung was significantly lower in the test group compared to the control group. The number
of peptide-induced interferon-γ secreting cells after challenge was higher and more frequent in
the test group than in the control group. Together, our results provide indications of a shapeable
PRRSV-specific cell-mediated immune response that may inspire future development of effective
PRRSV vaccines.
Keywords: porcine reproductive and respiratory syndrome virus (PRRSV); virus replicon particles
(VRP); classical swine fever virus (CSFV); viral vector; vaccine; polyepitope antigen; cytotoxic T cells;
cell-mediated immunity
1. Introduction
Porcine reproductive and respiratory syndrome virus (PRRSV) is a small-enveloped
virus with a single-stranded positive-sense RNA genome of 15 kilobases. PRRSV infections
cause reproductive failure in late gestation sows [1] and respiratory distress, particularly
in young pigs [2]. The level of virulence varies among strains, spanning from very mild
symptoms to the detrimental hemorrhagic ‘Porcine High Fever Disease’ caused by highly
virulent strains from South-East Asia [3] and the USA [4].
The virus belongs to the Arteriviridae family of the order Nidovirales and was originally
divided into genotypes 1 and 2, representing the European and North American/Asian
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genotypes, respectively. Recent revision of the Arteriviridae taxonomy has reclassified
the two genotypes into two distinct species: the Betaarterivirus suid 1 (PRRSV-1) and
Betaarterivirus suid 2 (PRRSV-2), respectively [5]. PRRSV-1 is further divided in three
subtypes and PRRSV-2 consists of nine lineages [6]. The two species are enzootic in most
swine producing countries and cause tremendous production losses worldwide [7–9].
Vaccination is the most common method to control the virus. The strongest protective
response is obtained using species-specific modified live virus (MLV) vaccines. The use of
MLV vaccines, however, has a number of drawbacks: (1) it is well documented that the MLV
vaccines may spread to naïve animals, which may end up with enhanced transmission,
reversion to virulence, recombination, and disease [10–14]; (2) vaccination of pregnant
sows with MLV vaccines in the last trimester may result in reproductive failures, or birth
of stillborn and/or persistently-infected piglets [15]; (3) MLV vaccines may persist in a
herd for months, or even years, making virus eradication difficult without production
stop; 4) MLV vaccines have a limited efficacy against heterologous field strains. Restrictive
measures to contain these safety issues have been established. As such, according to the
specific product descriptions, MLV vaccines registered in Europe are not approved for
use in PRRSV-negative herds and in breeding age boars (ema.europa.eu). Yet, there is
an urgent need for alternative PRRSV vaccines to ensure a safe and effective protection
against PRRSV.
Multiple vaccine strategies have been tested including killed virus, viral vectors,
vaccines based on recombinant protein and DNA with various antigens, delivery systems,
and adjuvants. The performance of these vaccines in terms of effect on viral clearance and
relief of symptoms are diverse (reviewed in [16,17]). Although they all succeed to induce
some degree of an immune response—characterized by virus-specific antibodies and T-cell
responses—none of them were capable of providing a sustained protective response against
a heterologous challenge.
Both T-cell responses and especially humoral immunity in response to PRRSV infection
have been investigated extensively (reviewed in [18]). The results of these studies are often
contradictive and the conclusions regarding the importance of T-cell responses in the
protective immune response against PRRSV are vague. It does appear, however, that
both neutralizing antibodies and interferon (IFN)-γ play an important role: in one study,
passive transfer of virus-specific antibodies provided protection against reproductive
failure and sterilizing immunity against a homologous strain, thus, completely bypassing
cell-mediated immunity [19]. Another study argued that a T-cell response was solely
responsible for the protective immunity of a PRRSV-1 challenge upon vaccination with an
MLV vaccine, since a virus-specific IFN-γ response was observed, while no neutralizing
antibodies were present [20].
Virus replicon particles (VRPs) represent an RNA vaccine platform that—similar to
viral vectors—can induce both humoral and cell-mediated immune responses through
sustained RNA replication and expression of vaccine candidate antigens [21,22]. In com-
parison to virus vectors, VRPs are safer and easier to control as they cannot package their
genome into infectious progeny virions unless the missing structural proteins are provided
by trans-complementation [23]. Consequently, once a cell has been infected with VRP,
the replicon multiplies inside the cell and the genes encoded by the VRP are translated
to protein. This activates the endogenous pathway for peptide presentation on major
histocompatibility complex (MHC) class I allowing for the generation of a CD8+ cytotoxic
T lymphocyte (CTL) response without any risk of infectious virus particle formation. VRPs
can be regarded as self-adjuvanting [24] since they trigger the innate immune pathways
similarly to infectious virus.
Several replicon-based vaccines have been tested in both human and animal trials and
have been licensed as commercial vaccines (replicon vaccines reviewed in [25,26]). A recent
experiment in the context of PRRSV described the vaccination of pigs with a recombinant
vesicular stomatitis virus VRP expressing the PRRSV structural proteins, GP2-5, M, and
the nucleocapsid protein N [27]. Although no reduction in viremia was observed following
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challenge with PRRSV, antibodies against the N protein were detected prior to challenge,
and an antibody response against GP3/GP4/GP5 was observed after PRRSV challenge in
the VRP-vaccinated animals two weeks earlier compared to the pigs that had received the
empty control VRP.
The majority of the studies describe replicons that express whole proteins or larger
antigenic fragments, but recent advances in custom DNA synthesis and next-generation
sequencing technologies have accelerated replicon development and facilitated the in-
tegration of specifically designed gene cassettes. In the present study, we describe the
development of a VRP-based vaccine using non-cytopathogenic classical swine fever virus
(CSFV) replicons targeting the induction of a sustained and cross-reactive T-cell response
against PRRSV-2. To this end, we used classical swine fever (CSF)-VRPs to express nine
different polyepitopes resulting from different combinations of a total of 33 conserved
PRRSV-2 T-cell epitopes verified previously as binders to relevant MHC class I swine
leukocyte antigens (SLA), SLA-1*04:01, SLA-1*07:02, and SLA-2*04:01 [28]. CSF-VRP was
chosen as the preferred platform because of the natural tropism of CSFV for antigen pre-
senting cells [29,30], because of the versatility of the platform [31], and because it was
used successfully to induce T-cell responses against influenza virus NP [32] and to prime
immune responses against PRRSV [27]. We characterized the VRPs in cell culture and in
a subsequent vaccination-challenge experiment of young pigs with MHC class I profiles
matching the selected epitopes. Our data showed that the VRP-induced T-cell response
alone did not protect against infection and disease but resulted in partial reduction of virus
load in the lung.
2. Materials and Methods
2.1. Polyepitope Design and Plasmid Construction
Polyepitopes were designed by a Python-based algorithm encoded to iteratively
recombine the individual PRRSV epitopes (previously verified to form peptide-MHC
complexes with recombinant SLA I and β2m [28]) in different successions interspersed with
random spacer amino acids, meanwhile optimizing for the lowest number of neoepitopes
in the regions spanning two neighboring PRRSV epitopes. In this context, neoepitopes
were defined as amino acid stretches of 8–11 residues that were predicted to bind to
either of 19 SLA class I alleles with a rank ≤4 using the prediction server, NetMHCpan
version 2.8. The optimized polyepitopes were reverse translated to cDNA sequences,
flanked by a 5′-terminal KasI and a 3′-terminal MluI restriction site for insertion into the
replicon plasmids (see below), and purchased from GenScript (Piscataway) as synthetic
gene cassettes codon-optimized for porcine tRNA.
The replicon constructs of the present study were based on the plasmid pA187-Npro-
IRES-C-delErns encoding a bicistronic CSFV replicon for transgene expression [31]. This
plasmid was derived originally from the full-length cDNA clone pA187-1 [33] by deleting
the Erns gene and introducing an internal ribosome entry site (IRES) between the Npro and
C genes. For the purpose of the present study, a synthetic gene cassette codon-optimized
for porcine tRNA and encoding the C-terminal part of Npro with a C138A substitution to
abolish inhibition of type I interferon induction by Npro, a porcine ubiquitin monomer
(Ub, GenBank accession: NP_001098779) mutated to prevent C-terminal cleavage (see
below), a hemagglutinin tag (HA), a KasI restriction site, the SIINFEKL epitope (epi), a MluI
restriction site, the FLAG tag, and a stop codon was obtained from GenScript (Piscataway)
and used to replace the ClaI-to-NotI fragment of pA187-Npro-IRES-C-delErns. As mentioned,
the codon for the C-terminal glycine (G76) of the Ub gene was mutated to express a
valine (G76V) in order to prevent cell-mediated cleavage of Ub from the downstream HA-
tagged polyepitope. The resulting plasmid was termed pA187-Npro-epi-IRES-C-delErns and
served as a backbone for different PRRSV-2 polyepitopes by replacement of the SIINFEKL
epitope with the polyepitope sequence of interest using the restriction sites KasI and MluI
(Supplementary data 1). All final constructs were verified by nucleotide sequencing before
they were used to rescue VRPs.
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2.2. VRP Rescue
The VRPs were rescued from plasmids as described elsewhere [31]. Briefly, plasmids
were linearized with the restriction endonuclease Srf l and RNA run-off transcription was
performed using the MEGAscript T7 kit (Ambion, Austin, TX, USA). One microgram RNA
was then used to electroporate 8 × 106 SK-6(Erns) cells maintained in Eagle’s minimum
essential medium (EMEM) supplemented with 7% horse serum (Håtunalab, Bro, Sweden)
and 0.25 mg/mL G418 (Calbiochem, Merck KGaA, Darmstadt, Germany). After three days
of incubation at 37 ◦C, the VRPs were harvested by two freeze-thaw cycles and the lysates
were clarified by centrifugation (P0 stocks). The VRPs were further propagated in SK-
6(Erns) cells by infection at a multiplicity of infection (MOI) of 0.1 followed by incubation
at 37 ◦C for 72 h to generate P1 and P2 stocks.
2.3. Titration of VRPs and PRRSV
The VRPs were titrated in SK-6(Erns) cells by end-point dilution and immunoperoxi-
dase staining using the anti-E2 monoclonal antibody (mAb) HC/TC26 [34] kindly provided
by I. Greiser-Wilke (Hannover Veterinary School, Hannover, Germany) and a horseradish
peroxidase (HRP)-conjugated rabbit anti-mouse IgG (Dako). Alternatively, the VRPs were
titrated in PK-15 cells using the mAb WH211 (APHA, RAE0242) and an HRP-conjugated
polyclonal goat anti-mouse serum (Jackson ImmunoResearch Laboratories, West Grove,
PA, USA). Titration of the PRRSV-2 strain used for challenge was performed in MARC-145
cells using the monoclonal antibody, SDOW17-A (RTI LLC) and HRP-conjugated rab-
bit anti-mouse serum (Dako). The SK-6(Erns) cells were maintained as described above,
and the PK-15 and MARC-145 cells were cultured in Dulbecco’s modified Eagle medium
supplemented with 5% fetal bovine serum (FBS).
2.4. Flow Cytometry
Flow cytometry (FCM) was applied to VRP-infected cells for the detection of the
FLAG-tagged epitope expression. Briefly, 105 SK-6 cells were infected with the VRPs
0 to 9 from the first passage (P1) stock or mock infected. Mock consisted of SK-6(Erns)
lysate obtained in parallel to the VRP stocks. In addition, VRPs rescued from the original
backbone replicon vector, pA187-Npro-IRES-C-delErns, were included as a negative sample
control as this replicon does not encode a FLAG tag. All infections were performed at a
MOI of 5 in the presence of 100 nM of the proteasome inhibitor epoxomicin (Sigma) or of
an equivalent amount of dimethyl sulfoxide (DMSO) as solvent control added 28 h post-
infection, in order to counter the expected proteasomal degradation of the ubiquitinylated
polyepitopes. After another 18 h, the cells were detached by trypsin treatment, fixed with
4% paraformaldehyde in phosphate buffered saline (PBS), and permeabilized with 0.1%
saponin in PBS. Infection was confirmed by the detection of the CSFV E2 protein with
the mAb HC/TC26 and AlexaFluor647-conjugated goat anti-mouse IgG2b (ThermoFisher,
Waltham, MA, USA). Polyepitope expression was confirmed by FLAG tag detection with
the F3165 mAb (Sigma, Kawasaki, Japan), and the phycoerythrin-conjugated goat anti-
mouse IgG1 (BioConcept, Allschwil, Switzerland). All antibodies were diluted in PBS +
0.3% saponin. The cells were washed with Cell Wash (BD Biosciences) after each treatment
and subjected to FCM (FACSCanto II, BD Biosciences).
2.5. SLA Genotyping
Sequence-specific SLA genotyping was performed by polymerase chain reaction
(PCR) on genomic DNA extracted from ethylenediaminetetraacetic acid (EDTA)-stabilized
whole blood from candidate experimental animals using primers specific for the super-
types SLA-1*04 (forward: 5′-GCCTGACCGCGGGGACTCT-3′, reverse: 5′-CTCATCG-
GCCGCCTCCCACTT-3′), SLA-1*07 (forward: 5′-GCCGGGTCTCACACATCCAGAT-3′, re-
verse: 5′-GGCCCTGCAGGTAGCTCCTCAAT-3′) and SLA-2*04 (forward: 5′-CCGAGGGAA
CCTGCGCACAGC-3′, reverse: 5′-CCCACGTCGCAGCCGTACATGA-3′). Amplicons were
sequenced by commercial Sanger sequencing (LGC Genomics) and identification of the
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alleles, SLA-1*04:01, SLA-1*07:02, and SLA-2*04:01, was performed by single nucleotide
polymorphism (SNP) analysis using CLC Main workbench 7.0.
2.6. Experimental Animals
Peptide-MHC I complex formation of the predicted epitopes included in the VRPs
were demonstrated experimentally with SLA-1*04:01, SLA-1*07:02, and SLA-2*04:01. There-
fore, only animals expressing these alleles were included in the polyepitope vaccination
and PRRSV-2 challenge trial. Thirteen pregnant sows from a Danish herd certified and
verified by serology to be free of PRRSV (results not shown) were genotyped. Four of
these were found to carry at least one of the three SLA alleles of interest. All 45 piglets
of the four sows (offspring from Danish Landrace-Yorkshire sows crossed with Duroc
boars) were genotyped, from which 18 SLA-matched piglets (8 females and 10 males) were
selected as experimental animals and purchased. The 4-week-old pigs were all housed
in the same pen in the biosafety level 3 agricultural (BSL-3Ag) animal isolation facility
at the National Veterinary Institute, Lindholm. Here, they were divided randomly into a
test group (N = 11) and a control group (N = 7), with blocking for an even distribution of
SLA-profile, litter of origin, and initial bodyweight (Table 1). Ear tag numbers were used
to identify the animals in order to ensure blinding (see below). The names were assigned
after the end of the experiment for easier distinction of test and control pigs. Seven weeks
after arrival, the pigs were separated in two pens with an even distribution of test pigs
and control pigs in each pen. Throughout the whole experiment the pigs had free access to
water and were fed on a daily basis with zinc-supplemented fodder purchased together
with the pigs (first two weeks) or Porkido 10,5 Ideal AU (DLG) (rest of period).









Calvin • • 8 2 2
Casper • • 9.6 2 1
Chloe • • 11.7 3 2
Charlotte • • 5.7 4 2
Charlie • • 8.5 1 1
Connor • • 7.1 1 1
Cameron • • 8.5 3 1
Test
Toby • • 8.9 1 1
Tracy • • 8.1 2 2
Trisha • • 9.2 2 1
Tyra • • 10.3 2 1
Tristan • • 6.1 3 2
Thomas • • 7.8 4 2
Tania • • 7.4 1 2
Tara • • 6.7 1 1
Tia • • 5.7 1 1
Tyson • • 10.2 1 2
Tina • • 10.8 3 2
Pigs were distributed between the control group (N = 7) and test group (N = 11) for an even distribution of swine
leukocyte antigens (SLA) profile, body weight, and litter. All pigs were kept in the same pen during the first seven
weeks after which they were split in two neighboring pens due to space constraints. Female pigs are in italic.
2.7. Experimental Setup of the In Vivo Study
The pigs in the test group were vaccinated with a titer-adjusted mix of the PRRSV
polyepitope containing VRPs (VRPs 1 to 9), while the pigs in the control group received
the VRP encoding the SIINFEKL control peptide (VRP 0, see Supplementary data 1).
Vaccinations were administered as intradermal injections (27G needle) of 0.5 mL 107
median tissue culture infectious dose (TCID50)/mL VRP from the P2 stock applied as five
spots of 0.1 mL each in the dermis of the right-side lateral neck region. The first vaccinations
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were given one week after arrival at days post vaccination (dpv) 0. This was followed by
two booster vaccinations at dpv 28, and 51. Challenge virus was administered intranasally
with 2 × 106 TCID50/animal of the Danish PRRSV-2 field isolate, DK-1997-19407B (cluster
5.2, GenBank accession KC862576), by spraying 2 mL virus solution into each nostril using
a syringe. Challenge was given at dpv 64 (Figure 1). The assignment of the pigs to vaccine
or control group remained unknown to the caretakers in charge of clinical evaluation
throughout the whole experiment.
Figure 1. Timeline of the vaccine-challenge experiment indicating the major interventions.
2.8. Clinical Observations
The pigs were monitored twice daily and a clinical score was assigned based on general
health condition (normal, mild lethargic, lethargic, or apathetic), respiration (normal,
increased respiration, respiratory distress, severe respiratory distress), and appetite (normal,
slow eating, not eating). Body weight was measured at dpv −1, days post challenge (dpc)
−1, and at necropsy. Rectal temperatures were measured at dpv −1, 1, 2, 3, 28 (2nd
vaccination), 29, 30, 31, 51 (3rd vaccination), 52, 53, 54, and 63 (one day before challenge,
dpc −1), and at dpc 1, 2, 3, 5, 7, 8, 9, 13, and 20.
2.9. Blood and Nasal Swab Sampling
Blood samples were collected from the jugular vein of all pigs at dpv 0, 14, 21, 41,
51; and dpc −1, 1, 2, 5, 7, 9, 13, and 20 for the preparation of serum and/or peripheral
blood mononuclear cells (PBMCs). The samples at dpv 0 were collected prior to vacci-
nation. Serum was recovered from non-stabilized tubes after coagulation overnight at
4 ◦C by centrifugation at 1000× g for 10 min at 4 ◦C and stored at −80 ◦C for subsequent
analysis. PBMCs were isolated from heparin-stabilized tubes by density centrifugation on
Lymphoprep (Stemcell) in 50 mL SepMate tubes (Stemcell) at 1200× g for 10 min at room
temperature (RT). Contaminating erythrocytes were lysed with lysis buffer (77 mM NH4Cl,
5 mM KHCO3, 63 µM EDTA in water) for 3 min at RT and washed with PBS + 2% FBS.
PBMCs were used the same day for immunological examination by IFN-γ enzyme-linked
immunospot (ELISPOT) assay after being counted by microscopy. Nasal swabs were col-
lected from all pigs at dpc −1, 1, 2, 5, 7, 9, 13, and 20 and placed in cryotubes containing
1 mL PBS and stored at −80 ◦C for subsequent analysis.
2.10. Tissue Sampling
Euthanasia was performed at dpc 26 and 27 by captive bolt stunning followed by
exsanguination by cutting the vena and arteria axillaris. Immediately thereafter, a visual
inspection of the lungs was performed, and three samples of approximately 1 cm3 of lung
tissue (left cranial, medial, and caudal lobes) were collected from each pig and kept at
−80 ◦C for subsequent analysis. Additionally, the draining lymph node of the vaccination
site, Ln cervicalis superficialis dorsalis, was excised from all pigs and cells were extracted
manually, separated from debris through a 100 µm cell strainer and washed with PBS + 2%
FBS. The cells were used the same day for immunological examination by IFN-γ ELISPOT
after being counted under a microscope.
2.11. Serology
The detection of serum antibodies against the CSFV E2 glycoprotein was performed
with serum from dpv −1 and 51 using a classical swine fever E2 competition enzyme-
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linked immunosorbent assay (ELISA) kit (CSFE2C-5P, ID-vet) following the manufacturer’s
instructions. The plates were analyzed at 450 nm using a ELx808™ absorbance microplate
reader (BioTek). The detection of serum antibodies against the PRRSV nucleocapsid protein
N was performed with serum from dpc −1, 7, 9, 13, and 20 using an IDEXX PRRS X3 Ab
Test (99-40959, IDEXX) following the manufacturer’s instructions with the sole modification
that the tetramethylbenzidine (TMB) color reaction was stopped with equivalent amounts
of 1M H2SO4 (in house), after which the plate was read at 450–630 nm using the ELx808™
absorbance microplate reader. Positive and negative controls were measured in duplicates,
while samples were performed in single measurements.
2.12. IFN-γ ELISPOT
MultiScreen IP filter 96-well plates (Millipore, MSIPS4510) were treated with 35%
EtOH for <60 s and coated with 250 ng/well mouse anti-porcine IFN-γ monoclonal anti-
body (clone P2F6, ThermoFisher) in PBS at 4 ◦C overnight. Plates were washed three times
in PBS and blocked with AIM-V albuMAX (31035025, ThermoFisher, Waltham, MA, USA)
at 37 ◦C, 5% CO2 for at least 1 h after which freshly isolated cells were seeded in presence
of stimuli as described below. Peptides used for stimulation (GenScript, Piscataway, NJ,
USA) were dissolved and stored as described in Supplementary Data 2. Following two
days of incubation at 37 ◦C, 5% CO2, the plates were emptied and the cells were lysed
by two times washing with ultrapure water, then three times with washing buffer (PBS +
0.01% Tween 20). Plates were incubated with 100 ng/well biotinylated mouse anti-porcine
IFN-γ mAb (clone P2C11, BD Biosciences) in reaction buffer (PBS + 0.01% Tween 20 + 0.1%
bovine serum albumin) on a shaker at RT for 1 h. The plates were washed four times and
incubated with 50 mU/well streptavidin-alkaline phosphatase-conjugate (11089161001,
Sigma-Aldrich, St. Louis, MO, USA) in reaction buffer on a shaker at RT for 1 h. Plates were
washed three times with washing buffer followed by two times with PBS. Spots were de-
veloped using 100 µL/well BCIP/NBT tablets (B5655, Sigma-Aldrich, St. Louis, MO, USA)
dissolved in 10 mL/tablet ultrapure water in the dark at RT for 5 min, and the development
was stopped under running tap water while the underdrain was removed. Still wet, the
plates were completely submerged in decontamination solution (1% VirkonS) for 30 min
prior to export from the BSL-3Ag facility in compliance with the biosafety regulations. The
plates were washed under running tap water and left to dry in the dark. Ultimately, the
spots were counted on an AID iSpot Reader Spectrum (Autoimmun diagnostika GmbH).
2.12.1. Pre-Challenge ELISPOT
ELISPOT assays using PBMCs isolated at dpv 0, 14, 27, 41, and 63 were designed to
screen for reactive peptides included in the VRPs pre-challenge. Twelve peptide-pools
were used for restimulation of the PBMCs representing a two-dimensional matrix with
six pools in each dimension containing five to six peptides each. Together, each of the
33 PRRSV peptides included in the VRPs was represented by exactly one pool in each
dimension. Stimulations with the VRP mixture used for vaccination and the PRRSV strain
used for challenge were also included together with their respective mocks. Peptide
stimulations were done with partial concentrations of 2 µM/peptide, while virus and VRP
stimulations were done at a MOI of 0.1. Unstimulated wells were included as baseline,
and wells stimulated with 1 µg/mL staphylococcal enterotoxin B (SEB) (S4881, Sigma-
Aldrich) were included as positive controls. All stimulations were seeded in duplicates
with 300,000 cells/well.
2.12.2. Post-Challenge ELISPOT
ELISPOT assays using PBMCs isolated at dpc 7 and 20 were designed to identify
individual reactive peptides among 14 peptides chosen from the 33 vaccine peptides.
Stimulations were done with individual peptides at concentrations of 5 µM. Unstimulated
wells were included as baseline, and wells stimulated with 1 µg/mL SEB were included as
positive controls. All stimulations were seeded in quadruplicates with 500,000 cells/well.
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Consequently, restimulation with virus and VRP were excluded from the setup due to
limitations in test capacity and number of PBMCs available. This setup was also used for
the ELISPOT assays using cells extracted from the lymph nodes, although with 300,000
cells/well only.
2.13. Quantification of Viral RNA
Viral RNA was purified from the challenge inoculum, serum samples, nasal swabs,
and lung tissue homogenate. The samples were clarified by centrifugation and RNA
extracted using the MagNA Pure LC Total Nucleic Acid Isolation Kit (03 038 505 001,
Roche, Basel, Switzerland) on a MagNA Pure LS Instrument (Roche, Basel, Switzerland).
Quantitative reverse transcription PCR (qRT-PCR) was performed using the Qiagen On-
eStep RT-PCR Kit (210210, Qiagen, Hilden, Germany) on an MX3005P QPCR System
(Agilent) with the following primers: forward: 5′-ATRATGRGCTGGCATTC-3′, reverse:
5′-ACACGGTCGCCC-TAATTG-3′. The probe was modified from the TEX-containing
version to contain HEX instead: 5′-(HEX)-TGTGGTGAATGGCACTGATTGACA-(BHQ2)-
3′ [35,36]. Cq values were converted to equivalents of TCID50 (TCID50eq) using a standard
curve based on a purified 10-fold dilution series of the challenge isolate. qRT-PCR was
performed in duplicates for all samples. Prior to purification, lung tissue homogenate was
prepared from cutouts of approximately 0.2–0.4 g of tissue homogenized in 1 mL EMEM
using lysing matrix D (MP bio) in a FastPrep FP120 cell homogenizer (Thermo Savant) for
60 s at speed 5.
2.14. Statistics
Positive signals upon restimulation in the ELISPOT data were identified by two criteria:
the first using the online (http://www.scharp.org/zoe/runDFR/, accessed September
2016) non-parametric distribution free resampling (DFR) tool as described by Moodie
et al. [37], and the second by defining a positive signal as a response with more than
twice the number of signal spots compared to the number of background spots with a
minimum of eight signal spots (ratio-2 method) [38]. This method furthermore allowed for
a quantitative analysis of the response magnitudes. The results of the two methods were
used to calculate relative percentage values of the responding peptides in order to compare
responders between groups.
p-values for the differences in lung tissue virus load between groups were calculated
using Mann–Whitney. A paired, two-tailed T test was used to test for significant peaks in
rectal temperature within the groups pre-challenge. An unpaired, two-tailed T test was used
to test for significant difference in rectal temperature between the groups post-challenge.
3. Results
3.1. Expression and Proteasomal Degradation of the VRP-Encoded PRRSV Polyepitopes
3.1.1. The PRRSV-2 Polyepitope Ensemble
The 33 individual epitopes used in this study were conserved among PRRSV-2 strains
and were selected from a large specific epitope pool based on in silico-predicted and
in vitro-verified binding-affinity and -stability to three relevant SLAs, as determined in a
previous study (Table 2) [28]. They were assembled into a total of nine polyepitopes that
were designed in pseudo-triplicates for each of the three SLAs. Pseudo-triplicate means
that for each SLA, three polyepitopes were designed with the same individual SLA-specific
epitopes, but in different successions to obtain a more robust expression of all epitopes
against potential translation and/or degradation artifacts related to primary structures.
As such, the pseudo-triplicates for the construction of VRP 1 to 3 were based on epitopes
specific for SLA-1*04:01, pseudo-triplicates for VRP 4 to 6 were based on epitopes specific
for SLA-1*07:02, and pseudo-triplicates for VRP 7 to 9 were based on epitopes specific for
SLA-2*04:01 (Table 3).
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Table 2. Peptides included in the VRPs, in post-challenge ELISPOT, and naturally expressed by the challenge strain.





















2 YAQHMVLSY − − • 0.9 4 • 1.1 60
√ √
4 YSFPGPPFF 0.2 37 † • 0.2 18,708 − −
5 RALPFTLSNY • 0.3 12 0.1 −
√
7 QVYERGCRWY • 0.3 682 • 4.5 168 • 0.7 209 †
√ √
9 IVYSDDLVLY − − • 0.5 13 − −
√
10 KVAHNLGFYF • 0.3 122 • 0.3 99
√
11 TRARHAIFVY • 0.3 60 0.2 −
√
12 LSFSYTAQF • 1.3 73
√ √
13 FTWYQLASY 0.1 92 † • 0.2 62 • 9.1 2
√ √
17 RTAIGTPVY • 0.5 57 • 0.2 1852 • − 385 †
√
18 YTAQFHPEIF − − • 0.2 24,378 • 0.4 −
√
19 LSDSGRISY • 1.1 10 • 0.2 383 0.2 4182 †
√ √
21 KVAHNLGFY • 1.5 4 • 2.8 11 − −
√ √
22 KIFRFGSHKW • 0.2 98 0.1 9 †
√
23 NISAVFQTYY • 0.1 413 • 0.9 6 • − 862
√ √
24 RTAPNEIAF • 2.1 4 0.1 −
√
25 ASDWFAPRY • 4.9 2 • 0.2 71 − −
√ √
27 RPFFSSWLV • 37.4 1
√ √
28 FVLSWLTPW − − • 0.2 1372 • 13.7 3
√ √
29 MVNTTRVTY 0.1 206 † • 0.2 47 − −
√
30 CVFFLLWRM • 0.2 283
√
33 ITANVTDENY 0.1 − • 0.3 69 − −
√
34 SSEGHLTSVY − − • 0.2 12,701 † 0.1 1692 †
√
36 LTAALNRNRW − − • 3.6 40
√ √
38 LSASSQTEY 0.1 91 † • 0.2 479 0.2 −
√
39 VRWFAANLLY • 2.7 44
√ √
43 TTMPSGFELY • − 576 • 0.8 6 0.2 1838 †
44 MSWRYSCTRY − − • 0.5 87 • 1.5 15
√
46 ALATAPDGTY − 607 † • 0.1 2736
√
48 WGVYSAIETW • 0.2 21,433
√
49 FLNCAFTFGY − − • 0.3 20 • 0.3 2069
√
50 NSFLDEAAY • 0.1 43 − −
√
53 MPNYHWWVEH • 0.6 32
√
Data on the 33 epitopes used in the polyepitopes. Provided information with regard to the three SLAs: Inclusion (•) of epitope in
SLA-specific VRP, measured binding stability (average dissociation half-life in decimal hour (h)), and measured binding affinity (average
equilibrium dissociation constant (nM)). †: only one successful affinity measurement was obtained. Hyphen (-): no successful measurements
were obtained (stability or affinity). Empty field: not tested.
Table 3. Polyepitopes assembled according to the SLA specificity of the peptides.
VRP SLA Specificity Epitopes Succession in Polyepitope Epitopes
VRP 1 SLA-1*04:01 19-23-43-25-24-17-7-22-10 9
VRP 2 SLA-1*04:01 23-7-22-10-25-24-43-19-17 9
VRP 3 SLA-1*04:01 19-17-7-22-10-43-25-24-23 9
VRP 4 SLA-1*07:02 34-33-10-5-18-17-13-29-46-43-2-50-28-39-19-30-11-25-23-4-49-53-7-27-44-38-9 27
VRP 5 SLA-1*07:02 13-18-38-27-23-11-25-19-7-53-46-2-17-4-33-49-9-39-5-28-10-29-44-30-34-50-43 27
VRP 6 SLA-1*07:02 2-13-34-33-18-23-50-53-5-28-39-7-29-46-17-9-49-25-4-30-27-43-11-19-44-38-10 27
VRP 7 SLA-2*04:01 23-13-44-7-2-48-28-12-18-36-17-49 12
VRP 8 SLA-2*04:01 2-12-23-44-7-18-13-48-36-17-49-28 12
VRP 9 SLA-2*04:01 13-12-28-2-44-7-48-36-17-18-23-49 12
Overview of the pseudo-triplicate polyepitopes for the formation of the VRPs 1–9. Epitope numbers refer to ID column in Table 2. SLA
specificity and number of epitopes for reference.
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3.1.2. VRPs Designed to Feed Ubiquitinated PRRSV Epitopes into the MHC-I
Presentation Pathway
For the generation of VRPs expressing the polyepitopes described above, the backbone
plasmid pA187-Npro-epi-IRES-C-delErns (Figure 2) was derived from pA187-Npro-IRES-C-
delErns encoding a bicistronic CSFV replicon used previously to express bioactive luciferase
and granulocyte macrophage colony-stimulating factor in SK-6 cells [31]. This backbone
vector was modified to contain a synthetic DNA cassette encoding the SIINFEKL epitope
as a control (VRP 0) that was replaced with the individual polyepitope cassettes of interest
described above to generate VRP 1 to 9. As such, the polyepitopes were expressed as
ubiquitin-linked and FLAG-tagged proteins. The C-terminal glycine of Ub was mutated
to a valine (G76V) in order to prevent cell-mediated cleavage of Ub from the downstream
polyepitope by ubiquitin C-terminal hydrolases. This has previously been shown to
ensure poly-ubiquitination and proteasomal degradation of the Ub-polyepitope chimera,
thereby favoring MHC-I-mediated peptide presentation [39]. The C138A substitution in
Npro prevents Npro-mediated inhibition of type I IFN induction, which is expected to confer
adjuvant activity to the replicons in vivo through innate immune activation [31,40]. The
annotated details of the nucleotide and amino acid sequences for the backbone plasmid
and the nine polyepitopes are available in Supplementary data 1.
Figure 2. Design of the backbone replicon A187-Npro-epi-IRES-C-delErns. The map of the backbone replicon (packaged in
VRP 0) used in this study is represented schematically, with the Npro gene shown in black, the structural protein sequences
in light gray, and the non-structural protein region in white. The cassette for ubiquitinated and tagged epitope expression is
shown in dark gray and encodes a non-cleavable ubiquitin (Ub), a haemaglutinin tag (HA), an epitope site, and a FLAG
tag. Additionally, a C138A mutation was introduced in Npro to destroy the Npro-mediated interferon regulatory factor 3
degradation (♦), and the sequence coding for the SIINFEKL control epitope was flanked by an upstream KasI restriction site
(
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3.1.3. Verification of Polyepitope Expression and Proteasomal Degradation in Cell Culture
The backbone plasmid was used for the rescue of VRP 0 expressing the SIINFEKL
control epitope, and the constructs encoding the nine individual polyepitopes resulted in
VRP 1 to VRP 9, respectively (see Table 3). FCM analysis of cells transduced with VRPs at a
MOI of 5 confirmed VRP expr ssion by CSFV E2 detection, and the tagged polyepitope
expression and pr t asomal degradation were a alyzed by FLAG tag etecti n under
epoxomicin or DMSO solvent control treatment. The results are summarized in Figure 3A
with a representative example of the FCM gating strategy for VRP 6 shown in Figure 3B.
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Figure 3. Verification of VRP infectivity and polyepitope expression in SK-6 cells. (A) 105 cells
were infected at a MOI of 5 with the VRPs 0 to 9 or the VRP lacking FLAG (A187-Npro-IRES-C-
delErns) or mock-infected as control. Twenty-eight hour post-infection cells were treated with the
proteasome inhibitor epoxomicin (100 nM) or dimethyl sulfoxide (DMSO). After an additional 17.5 h,
the percentage of cells expressing the polyepitope (top panel) and the percentage of infected cells
(bottom panel) were determined by FCM using anti-FLAG and anti-E2 antibodies, respectively. At
least 36,000 events were acquired for each sample. (B) The FCM plots of VRP 6-infected cells under
DMSO versus epoxomicin treatment are shown as an example.
The threshold for infectivity (E2 detection, horizontal line) was defined based on
the epoxomicin-treated mock-infected sample, and the threshold for FLAG tag detection
(vertical line) was defined based on the epoxomicin-treated sample infected with the
FLAG-negative VRP rescued from the original plasmid, pA187-Npro-IRES-C-delErns (Sup-
plementary data 3). All VRPs were highly infectious and resulted in approximately 80% of
E2-positive cells. Polyepitope expression was detected for all constructs in 1% (VRP 9) to
22% (VRP 5) of the cells analyzed, but only when proteasomal degradation was inhibited
with epoxomicin (Figure 3A and Supplementary Data 3). The FLAG-tagged polyepitope
expression with VRPs 7 to 9 was remarkably weaker (1–2% of all cells) compared with VRPs
0 to 6 (5–22% of all cells). This was an interesting observation, as the VRPs 7 to 9 represent
SLA-2*04:01-specific polyepitopes as opposed to the other epitopes that are specific for
the other two SLAs. Collectively, these results show that all infections were successful,
and indicate that the polyepitope expression, as expected from the Ub linkage, undergoes
the proteasomal degradation necessary for peptide-MHC class I complex formation and
peptide presentation. If one assumes that the epoxomicin treatment does not provide
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complete proteasomal inhibition, one may postulate that the proportion of transduced cells
expressing the polyepitope may be higher than what we measured in our assay.
3.2. The Vaccination-Challenge Trial
3.2.1. Clinical Monitoring during the Vaccination and Challenge Phase
No virus-related clinical signs were seen in any of the pigs during the experimental
period and all pigs had a normal weight gain (data not shown). However, moderate but
statistically significant variations in rectal body temperature (up to 40.6 ◦C) did reflect
the second and third vaccination events. Following challenge, no difference in rectal
temperature between the two groups was observed (Figure 4A). This is in accordance with
previous studies using this field strain [41].
Figure 4. The vaccination challenge trial. (A) Rectal temperature throughout the experiment. The black and grey lines
represent the average temperatures of the test group and the control group, respectively. Error bars indicate the standard
deviations. The black arrowheads indicate the vaccination events. The white arrowhead indicates the challenge of the pigs
with PRRSV-2. Before challenge, asterisks indicate group-wise temperature peaks that are significantly different from the
previous day calculated using a two-tailed paired Student’s T-test (*: 0.05≥ p > 0.01; **: 0.01≥ p > 0.001). After challenge, no
significant differences in body temperature were observed between the two groups as calculated using a two-tailed unpaired
Student’s T-test. (B) Seroconversion following vaccination. Box diagram of the anti-E2 inhibition ELISA performed at dpv 0
and dpv 51 illustrating that the pigs responded to the vaccine vector by producing antibodies against the classical swine
fever virus (CSFV) protein E2. The upper and lower edges of the boxes represent maximum and minimum signal-to-noise
percentage values, respectively. The mean values are represented by the middle lines. The positive (11, 85) and negative
(100) control values are indicated by lines in the space between the two boxes. The shaded area represents the threshold
range. Note that no data points were observed in this area. (C) Seroconversion to PRRSV following challenge infection.
Line diagram of the PRRSV Ab ELISA showing that all pigs responded to the challenge by producing antibodies against
PRRSV N.
3.2.2. Seroconversion Demonstrated In Vivo Replication of Both the Replicon Vaccine and
the Challenge Virus
Two vaccinations at 28 days interval were sufficient to induce a strong seroconversion
against the vaccine vector as measured with an anti-E2 competition ELISA on day 51
post-vaccination, immediately before the third VRP injection (Figure 4B; optical density
(OD) span 9–29%, positive < 50), while all pigs were clearly seronegative for E2 before the
first vaccination (Figure 4B; OD span: 76–148%, negative > 60). Due to the observation
made by Suter et al. [31] that only pigs immunized with live CSF-VRP seroconverted
towards E2, whereas pigs immunized twice with UV-inactivated CSF-VRP did not, our
results indicated that the VRP-encoded genes were efficiently transcribed and translated
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into protein in the vaccinated animals. However, the vaccination had no effect on the
kinetics of the PRRSV-specific antibody response against the nucleocapsid protein N after
challenge as shown with the semiquantitative IDEXX PRRS X3 Ab Test kit on days −1, 7, 9,
13, and 20 post-challenge. All animals mounted an antibody response against PRRSV from
day 7 post-challenge, with no difference between the groups (Figure 4C).
3.3. The Polyepitope Vaccination Induced Peptide-Specific T-Cell Responses
With PBMC collected during the vaccination period before challenge infection the IFN-
γ ELISPOT revealed non-specific spots in all wells including the non-stimulated controls,
thereby making it impossible to identify clearly peptide-specific signals (data not shown).
An improved IFN-γ ELISPOT setup was performed with PBMC collected on days 7 and 20
after challenge and in part with lymph node cells obtained at necropsy. A higher resolution
was obtained from this setup by increasing the number of replicates and the number of cells
per well. In addition, only individual peptides and at higher concentrations were used for
restimulation instead of peptide pools. As a tradeoff, only 14 peptides could be included
in the assay, and restimulations with virus and VRP were excluded due to limitations
in the number of PBMCs available. The 14 selected peptides (ID 2, 7, 12, 13, 19, 21, 23,
24, 25, 27, 28, 36, 39, and 44) were chosen based on their in vitro binding capacities (see
Table 2). Figure 5 shows the restimulation signals (ELISPOT counts) for each individual
animal and peptide, and Figure 6 shows a compilation of these results per group. The
results are interpreted using the two statistical methods ratio-2 and DFR. Their results are
mostly overlapping, but while DFR is a well-established statistical method it only provides
a qualitative output, whereas a quantitative comparison can be obtained with the ratio-2
method as seen in the top panel of Figure 6A. For either method, significant responders are
indicated in the middle and bottom panels of Figure 6A, respectively. Regardless of the
method, the test group clearly shows more frequent and stronger responses of the PBMC
compared to the control group, thereby suggesting an effect of the vaccine in the induction
of a T-cell response. The lymph node cells were overall much less responsive than the
PBMCs with only three responder pigs out of 18. Nevertheless, these were all from the test
group. The general response-dominance of the test group still prevailed after accounting
for the unequal number of pigs in the two groups, as presented in Figure 6B.
It is worth noting that pig “Toby” responded to peptide 44 (MSWRYSCTRY) at dpc 7,
although the peptide had a mismatch compared with the corresponding sequence encoded
by the PRRSV challenge strain (MSWRYACTRY). It is unlikely that this peptide-specific
response was induced by the challenge virus, since in that case, the A6S polymorphism
would introduce a hydroxylic group of serine in the T-cell receptor (TCR)-binding middle
part of the peptide. This substitution would supposedly be detrimental for the binding of a
TCR primed by the flat and aliphatic alanin-containing challenge version. This is a good
indication that the response originated from the VRP-encoded peptide rather than from
the virus.
The detailed analysis revealed that despite the general response-dominance of the
test group, surprisingly no animal responded to the same peptide twice, i.e., at 7 and
20 dpc, according to the DFR method, and only one animal (“Thomas”, peptide 28) did so
according to the ratio-2 method. This indicates that peptide-specific responses were not
dominated by single clones but covered several peptides with low response levels.
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Figure 5. Overview of cell-mediated immune responses to peptides post-challenge. At dpc 7 and 20,
5 × 105 freshly purified peripheral blood mononuclear cells (PBMCs) were restimulated separately
with 14 selected peptides and with media as a background control. At euthanasia (dpc 26/27), 3× 105
cells derived from the lymph node were treated the same way and the counts were normalized to
5 × 105 cells/well for comparison with the PBMC counts. The response to restimulation is presented
here as columns indicating the average number of IFN-γ spot forming cells (SFC) in response to
restimulation with peptide (signal) minus the average number of SFC in response to restimulation
with medium (background). Error bars represent the corresponding standard deviations. Upper
edges of the gray area represent the subtracted average backgrounds for reference. Dashed lines
indicate ratio-2 thresholds. This is defined either as 2 × background, or as 8 representing the limit of
detection in cases where 2 × background is less than 8. Black columns represent positive peptide
responses according to the DFR method. Peptides are indicated on the x-axis with reference to the ID
column in Table 2.
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Figure 6. Summary of cell-mediated immune responses to peptides post-challenge. (A) The top panel represents the average
magnitude of significant positive responses per pig according to the ratio-2 method; the middle panel represents the number
of pigs/group with a significant positive response to the peptides according to the ratio-2 method; and the bottom panel
represents the number of pigs/group with a significant positive response to the peptides according to the DFR method.
Gray fill: control group (N = 7); black fill: test group (N = 11). The peptides are indicated on the x-axis with reference to the
ID column in Table 2. (B) Relative comparison of responding peptides according to date, group, and statistical method. Each
column was calculated using the formula: (responding peptides)/(tested peptides)/(number of pigs in the specific group).
In summary, the pigs of the test group have a generally higher response frequency
and magnitude than the pigs of the control group, thereby indicating a vaccine-mediated
induction of a T-cell response.
3.4. The Polyepitope Vaccination Did Not Prevent Viremia, But Resulted in Reduced Virus Load in
the Lung
In order to determine the protective potential of the VRP-mediated polyepitope
vaccination, the PRRSV load was analyzed by qRT-PCR in nasal swabs and serum on days
5 and 13 after challenge. The nasal swab samples were combined in one pool per group
while the sera were tested individually. Very low levels of virus were detected in the nasal
swabs, with no apparent trend between groups (data not shown). In the serum samples
collected on day 5 and 13 post-infection, the TCID50 equivalents as determined by qRT-
PCR were overall higher, but there were no differences between the groups (Figure 7A),
showing that the vaccination did not decrease the level of viremia. The virus load was also
determined in lung tissue samples collected from the cranial, middle, and caudal parts
of the lung. Here, slight differences in TCID50 equivalents per gram tissue between the
groups were observed in the middle parts (p = 0.069), and significant differences were
found in caudal (p = 0.035) parts of the lungs, which may be attributed to the vaccination
(Figure 7B).
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Figure 7. Virus load in serum and lung tissue analyzed by qRT-PCR. (A): Virus load in the serum at dpc 5 and 13 given
in TCID50 equivalents per ml serum. (B): Virus load in the lung tissue from cranial, middle, and caudal parts of the lung
prepared from cutouts of 0.2–0.4 g and normalized to TCID50 equivalents per 1 g of tissue. (C): Virus load in lung tissue
from test pigs only, displayed as non-T-cell-responders versus T-cell-responders at dpc 7, differentiated using the ratio-2
method. All P-values were calculated using Mann–Whitney. All measurements were performed in duplicates and were
converted from cq-values using a standard curve based on a purified 10-fold dilution series of the challenge isolate. Group
medians are indicated with a line. Virus load in the lung tissue from cranial, middle and caudal parts of the lung were
prepared from cutouts of 0.2–0.4 g and normalized to TCID50 equivalents to 1 g of tissue.
In general, PRRSV-specific T-cell response is not detected within the first four weeks
after infection [42–45]. Seen in that light, five test-group pigs stand out from the remainders
of the group by having responded clearly to peptides already seven days after infection
according to either the ratio-2 method alone (“Tyson”) or both methods (“Toby”, “Trisha”,
“Thomas,” and “Tina”). This suggests that the IFN-γ ELISPOT responses at day 7 post-
challenge were primed by the vaccination. Revisiting the viral load data in this new context
did again not reveal any differences in viremia between the groups (data not shown), but
substantiated the differences of viral load in the lungs. This was particularly the case in
the middle part of the lung, where a significant difference was observed when these early
responders were compared with the rest of the test-group pigs that did not show a T-cell
response on dpc 7 (Figure 7C). This correlation between reduced viral load and early T-cell
response is indicative of a vaccine-induced protective response.
4. Discussion
The present study explored a rational approach for the induction of PRRSV-specific
T-cell response through vaccination with CSF-VRPs expressing conserved PRRSV-2 MHC
class I epitopes selected from a previous study [28]. The epitopes and experimental
animals were matched in terms of MHC class I-restriction and -profile, respectively, and
the VRPs were constructed to induce ubiquitination and endosomal processing of peptides
for optimal presentation in peptide-MHC class I complexes. While the vaccination had
no effect on the prevention of infection and viremia, there was evidence of a virus load
reduction in the lungs, suggesting a contributing protective effect of a VRP-mediated
polyepitope-induced T-cell response.
The rationale behind choosing the VRP technology as vaccine platform was the fact
that it clearly avoids the major drawbacks, such as vaccine virus spread, recombination
and reversion to virulence, and the risks of reproductive failures and weak-borne piglets as-
sociated with MLV application during the last trimester of gestation. Due to the replicative
properties of the VRP, their tropism for antigen presenting cells, and the replicon-mediated
innate immune activation, VRPs are capable of inducing a good immune response, mean-
while maintaining absolute safety and high adaptability through simple and flexible genetic
engineering [29,31]. Several examples already exist for other viruses where replicon- or
viral vector-based vaccines expressing transgenic single epitopes or polyepitopes were ca-
pable of inducing a CTL response. In many cases, protective immunity upon challenge has
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even been successfully established [46–49]. The CSF-VRP, like the virus they are derived
from, have a tropism for dendritic cells (DC) and both conventional DCs (cDC) and plasma-
cytoid DCs (pDC) are early targets for the virus [29]. During normal CSFV infections, both
the Npro and Erns proteins of CSFV prevent type I IFN induction, respectively, by targeting
IFN regulatory factory 3 for degradation [40,50] and by interfering with Toll-like receptor
7-mediated pDC activation in yet unknown intracellular compartments, a mechanism
that is dependent of the RNase activity of Erns [51]. In the CSF-VRP applied here, these
activities were both abolished by a mutation in Npro and by deletion of Erns. A previous
study in pigs vaccinated intradermally with A187-delErns, a CSF-VRP related to the VRP
used here, showed a clear T-cell response as measured by increased IFN-γ production after
ex vivo re-stimulation of T-cells with CSFV [52]. In a study attempting to determine the
source of CSFV-induced IFN-γ, it was demonstrated that CD3+CD4-CD8αhigh, consistent
with CTLs, were the initial source of CSFV-specific IFN-γ producing cells upon challenge
of animals vaccinated with an attenuated CSFV C-strain. In contrast, no T-cell IFN-γ
was detectable upon challenge of unvaccinated animals that developed clinical signs of
disease [53]. A CSF-VRP based vector vaccine was also shown to induce both a CD4 and
CD8 T-cell response against nucleoprotein of influenza virus, confirming the suitability of
VRP to induce cell-mediated immunity [22,32].
In the present study it was hypothesized that a PRRSV-specific T-cell response, as
indicated by PRRSV-induced IFN-γ secretion, should result from CTLs activated via their
TCRs by cognate PRRSV peptide-MHC complexes presented by antigen-presenting cells.
As such, the central concept of the study was to use only peptide-MHC combinations that
had previously been identified as stable binders [28]. Consequently, only experimental
animals expressing at least two of the SLA alleles of interest were included in the animal ex-
periment. Out of the 33 selected epitopes, three sets of three SLA-specific polyepitopes were
created in pseudo-triplicates. The purpose of the SLA-matching polyepitopes was to allow
‘individualized’ vaccination by administration of a mixture of polyepitopes corresponding
to the SLA profiles of the individual animals. However, this strategy could only be partially
fulfilled in the present study. The design of pseudo-triplicates was to ensure a more stable
expression of all epitopes against potential translation and/or degradation artifacts related
to primary structures. The nine different polyepitopes were inserted into the expression
cassette of the CSFV replicon by replacing the SIINFEKL control epitope. The cassette had
two important features: firstly, a non-cleavable ubiquitin molecule upstream of the epitope
site was expected to feed the polyepitope into the MHC-I presentation pathway via the
immunoproteasome [39], and secondly, a FLAG tag downstream of the epitope served to
detect polyepitope translation. Both features were verified successfully for all VRPs by
FCM on infected SK-6 cells.
Indications of both vaccine-specific T-cell responses and reduced viral load in the
lungs were observed in our results. In spite of this, the protective effects were only partial
and the T-cell response readouts were highly variable and of low magnitude. This is
consistent with previous findings in which a recombinant adenovirus vector expressing
PRRSV polyepitopes was successfully shown to induce significant epitope-specific IFN-
γ responses in a vaccine-challenge experiment [54]. In this latter study, this was not
sufficient to confer full protection, but nevertheless, the vaccinated animals showed a
higher challenge virus clearance rate than the sham-vaccinated animals.
In our study, the reasons for only partial protection induced by the vaccine may
be related to insufficient VRP-induced priming of the CTLs. The chain of events from
vaccination to CTL priming is long and involves several steps subject to potential erroneous
processing that may ultimately result in unsuccessful priming. An important first step is
the activation of DCs for subsequent migration to, and antigen presentation in the lymph
nodes [55]. This step is unlikely to be the cause of unsuccessful priming due to the features
of the CSF-VRP platform described above and to the evidence of strong antibody responses
to the CFSV E2 protein. Thus, assuming that infection and activation of antigen presenting
cells was not the bottleneck of a more consistent and strong T-cell response, failures in
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intracellular processes related to polyepitope expression and processing may be responsible.
In this context, epitope abundance and insufficient peptide-MHC complex stability are
relevant parameters. This is evident by the low expression levels shown with FCM and
by the fact that immunoblot analysis of lysates of cells treated in vitro with epoxomicin
and infected with VRP failed twice to show visible bands (data not shown). Regardless,
the vaccination experiment was continued as intended, since vector DNA sequencing
confirmed the presence of the expected cassette and flow cytometric analyses of VRP-
infected SK-6 cells indicated correct polyepitope expression. Of note, all analyses indicated
low levels of protein expression, which was, however, not considered a hindrance to CTL
priming. Following translation, the amount of individual epitopes would have decreased
further upon proteasomal degradation and N-terminal trimming by aminopeptidases,
processes that would undoubtedly eliminate a fraction of the epitopes. One study indicated
that the sets of peptides produced by either the conventional or the immunoproteasome
differ more than expected [56]. This is highly relevant due to the fact that activated DCs
mainly contain the latter. Ultimately, the peptide-MHC complex stability of the selected
epitopes may for some of the peptides not have been sufficiently high to maintain complex
formation long enough for T-cell encounter and recognition to occur. The combination of
these aspects could have resulted in a very low rate of peptide-MHC-TCR encounters on
the surface of infected cells, which may explain the poor immune priming observed. We
measured systemic T-cell responses in PBMCs, but this may not fully reflect the local T-cell
responses to the challenge infection in the airways. Analysis of local resident memory T
cells obtained by bronchoalveolar lavage (BAL) would most likely have increased numbers
of PRSSV-specific T cells as recently shown with swine influenza [57]. Indeed, CTLs have
been reported to play a crucial role in combatting PRRSV at the site of infection, in lungs
and in BAL [58].
An alternative or additional cause of the low T-cell responses observed in our study
could be that the primed CTL response after vaccination was inhibited by the PRRSV
challenge infection. PRRSV is notoriously known for its multiple immunoevasive mecha-
nisms (reviewed in [59]) among many others are the downregulation of SLA-I molecules
on the surface of infected cells [60], the increased secretion of interleukin-10 (IL-10), and
the activation of regulatory T-cells, that could drive primed CTLs into quiescence. The
low quality of pre-challenge ELISPOT precludes a valid analysis of T-cell responses to
vaccination only and PRRSV-induced immunosuppression could explain at least part of
the low IFN-γ responses and the weak effect on virus load after challenge.
It is interesting that five test animals showed increased viral clearance in the lungs
when compared to the remainders of the test group. As dictated by the central concept
that a T-cell response would be the result of stable peptide-MHC bonds, all the selected
epitopes were verified as binders to either of the three SLA alleles. As such, the animals
included in the experiment did all express at least two of these alleles. The screening
method to identify these animals was based on sequence-specific SLA genotyping of only
these three SLA alleles and not by complete SLA genotyping. It is, thus, a possibility that
the five animals with increased viral clearance had an untyped SLA allele in common that
was capable of mounting a strong T-cell response via interactions with one or more of the
epitopes included. In general, pigs express a paternal and a maternal allele of each of the
three SLA class I loci, meaning that each pig expresses between three and six unique alleles.
In our case, the pigs were offspring of mixed races, thereby increasing the likelihood of
them expressing six rather than three unique alleles, which could certainly play a role in
the big variations of induced T-cell responses.
The large diversity of SLA haplotypes is an evolutionary advantage to avoid escape
mutants of the virus, but imposes a challenge with respect to developing a rational vaccine
platform based solely on CTL epitopes. One way to approach broad SLA coverage is
to develop a library of SLA-specific polyepitopes, of which singlet polyepitopes can be
combined into an ‘individualized’ vaccine shot exactly matching the SLA-profile of the
target animal. This was the approach pursued in the present study. An alternative approach
Vaccines 2021, 9, 208 19 of 22
is to develop a more general and uniform CTL epitope-based vaccine consisting of an
ensemble of carefully selected epitopes that in combination will cover the diversity and
individual abundance of both viral strains and SLA haplotypes. The PopCover algorithm
does exactly that and was also used to select the epitope candidates for this study [28,61]. A
major limitation of this approach—and the reason it was not used in the present study—is
the enormous amount of labor required to validate the predicted peptide-SLA binding
capacities in vitro. Regardless, a full SLA profile of the experimental animals could have
revealed patterns correlating with the observations, why full SLA genotyping is encouraged
for future studies of this type.
This study describes a rational approach for the induction of a PRRSV-specific CTL
response via vaccination with VRPs expressing conserved PRRSV-2 MHC class I T-cell epi-
topes and deliberately omitting a humoral antibody response to PRRSV structural epitopes
to dissect the importance of T-cell based immunity. Although the response magnitude was
lower than expected, our results suggest that a T-cell response was established and that
some degree of protection was obtained in five out of the 11 test pigs. The challenge strain
used in the present study belongs to the clade 5.2, which is the only clade circulating in
Europe. Despite that this strain causes severe clinical signs in the field, it is difficult to
reproduce severe clinical signs and extended viremia under experimental conditions [41].
It is possible that the differences between the vaccinated and unvaccinated animals would
have been clearer if a more pathogenic strain were used for challenge. However, a clear
relationship between pathogenicity/virulence and induction of T cell responses has not
been established [58]. Ultimately, our attempt to boost the CTL priming by administering
booster vaccinations may have been impaired by antibody responses against the structural
protein E2 used as positive control for seroconversion in the present setup. In future
trials, CSF-VRPs lacking all of the structural protein genes may yield more efficacious
booster responses. In any case, in a final setup, CSFV E2 needs to be excluded from any
PRRSV vaccine to prevent interference with CSF surveillance, and for a vaccine with better
protective efficacy, relevant epitopes for protective antibody responses to PRRSV needs to
be included. With this, it can be concluded that CSF-VRP represent a potential platform
for epitope vaccination to induce a T-cell response with protective properties, but further
optimization of epitope selection and delivery is needed.
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